Myeloid marker S100A8/A9 and lymphocyte marker, soluble interleukin 2 receptor: Biomarkers of hidradenitis suppurativa disease activity?

British Journal of Dermatology

Volumn 168, Issue 6, 2013, Pages 1252-1258

  Wieland, C W ^a   Vogl, T ^b   Ordelman, A ^a   Vloedgraven, H G M ^a   Verwoolde, L H A ^a   Rensen, J M ^a   Roth, J ^b   Boer, J ^a   Hessels, J ^a  

^a DEVENTER HOSPITAL   (Netherlands)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN A; CALGRANULIN B; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LYMPHOCYTE SURFACE MARKER; LYSOZYME; SOLUBLE INTERLEUKIN 2 RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SUPPURATIVE HIDRADENITIS;

ADULT; AGED; BIOLOGICAL MARKERS; CALGRANULIN A; CALGRANULIN B; CASE-CONTROL STUDIES; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MURAMIDASE; MYELOID CELLS; PEPTIDYL-DIPEPTIDASE A; RECEPTORS, INTERLEUKIN-2; ROC CURVE; YOUNG ADULT;

EID: 84876276795     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12234     Document Type: Article

References (36)

1. Jemec GB, Heidenheim M, Nielsen NH,. Hidradenitis suppurativa- characteristics and consequences. Clin Exp Dermatol 1996; 21: 419-23.
2. Alikhan A, Lynch PJ, Eisen DB,. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009; 60: 539-61.
3. van der Zee HH, Laman JD, Boer J, Prens EP,. Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol 2012; 21: 735-9.
4. Canoui-Poitrine F, Revuz JE, Wolkenstein P, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009; 61: 51-7.
5. Boer J, Weltevreden EF,. Hidradenitis suppurativa or acne inversa. A clinicopathological study of early lesions. Br J Dermatol 1996; 135: 721-5.
6. Sotiriou E, Apalla Z, Ioannidos D,. Etanercept for the treatment of hidradenitis suppurativa. Acta Derm Venereol 2009; 89: 82-3.
7. Blok JL, van Hattem S, Jonkman MF, Horváth B,. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol 2013; 168: 243-52.
8. van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol 2011; 164: 1292-8.
9. Fimmel S, Zouboulis CC,. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol 2010; 2: 9-16.
10. van der Zee HH, van der Woude CJ, Florencia EF, Prens EP,. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Br J Dermatol 2010; 162: 195-7.
11. Selroos OB,. Biochemical markers in sarcoidosis. Crit Rev Clin Lab Sci 1986; 24: 185-216.
12. Miyoshi S, Hamada H, Kadowaki T, et al. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest 2010; 137: 1391-7.
13. Matusiak Ł, Bieniek A, Szepietowski JC,. Soluble interleukin-2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging. Biomarkers 2009; 14: 432-7.
14. Chan JK, Roth J, Oppenheim JJ, et al. Alarmins: awaiting a clinical response. J Clin Invest 2012; 122: 2711-19.
15. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13: 1042-9.
16. Kerkhoff C, Voss A, Scholzen TE, et al. Novel insights into the role of S100A8/A9 in skin biology. Exp Dermatol 2012; 21: 822-6.
17. Frosch M, Vogl T, Seeliger S, et al. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2003; 48: 2622-6.
18. Frosch M, Ahlmann M, Vogl T, et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1β form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009; 60: 883-91.
19. van Zoelen MA, Vogl T, Foell D, et al. Expression and role of myeloid-related protein-14 in clinical and experimental sepsis. Am J Respir Crit Care Med 2009; 180: 1098-106.
20. Averill MM, Kerkhoff C, Bornfeldt KE,. S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol 2012; 32: 223-9.
21. Lee Y, Jang S, Min J, et al. S100A8 and S100A9 are messengers in the crosstalk between epidermis and dermis modulating a psoriatic milieu in human skin. Biochem Biophys Res Commun 2012; 423: 647-53.
22. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010; 4: 7-27.
23. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012; 18: 1894-9.
24. Benoit S, Toksoy A, Ahlmann M, et al. Elevated serum levels of calcium-binding S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis. Br J Dermatol 2006; 155: 62-6.
25. Ma D, Li Y, Hackfort B, et al. Smoke-induced signal molecules in bone marrow cells from altered low-density lipoprotein receptor-related protein 5 mice. J Proteome Res 2012; 11: 3548-60.
26. Wolk K, Warszawska K, Hoeflich C, et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol 2011; 186: 1228-39.
27. Hurley H,. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus. In: Dermatologic Surgery: Principles and Practice (, Roenigk RH, Roenigk HH Jr, eds). New York: Marcel Dekker, 1989; 729-39.
28. Roth J, Teigelkamp S, Wilke M, et al. Complex pattern of the myelo-monocytic differentiation antigens MRP8 and MRP14 during chronic airway inflammation. Immunobiology 1992; 186: 304-14.
29. Foell D, Wittkowski H, Vogl T, Roth J,. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81: 28-37.
30. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123: 450-60.
31. Manitz MP, Horst B, Seeliger S, et al. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol Cell Biol 2003; 23: 1034-43.
32. Frosch M, Strey A, Vogl T, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43: 628-37.
33. Sartorius K, Emtestam L, Jemec GB, Lapins J,. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009; 161: 831-9.
34. Sekimoto R, Kishida K, Nakatsuji H, et al. High circulating levels of S100A8/A9 complex (calprotectin) in male Japanese with abdominal adiposity and dysregulated expression of S100A8 and S100A9 in adipose tissues of obese mice. Biochem Biophys Res Commun 2012; 419: 782-9.
35. Mortensen OH, Nielsen AR, Erikstrup C, et al. Calprotectin: a novel marker of obesity. PLoS ONE 2009; 4: e7419.
36. Cobanoglu N, Dalkan C, Galip N, et al. Is calprotectin a marker of tobacco smoke related inflammation? A pilot study in children. Inhal Toxicol 2012; 24: 486-91.